Anticipated Milestones
NEXT GENERATION ANTHRACYCLINE - ANNAMYCIN ANTICIPATED MILESTONES
Clinical Trials - Complete cohort of 150 mg/m2 - prior trial recommended Phase II dose (RP2D)
Announcement of initial clinical data for Annamycin trial
Announcement of RP2D for Poland Trial
Poland clinical trial (MB-105) begins Phase II
Approach FDA on U.S. trial (MB-104) on dose expansion using Poland trial data
Announce additional clinical research in lung and metastatic lung cancers
POTENTIAL TIMEFRAME
Accomplished and ongoing 2019
Accomplished and ongoing 2019
2020
2020
2020 (Fast Track Approved)
2020
IMMUNE/TRANSCRIPTION MODULATOR - WP1066 ANTICIPATED MILESTONES
Clinical Trials WP 1066 - Announcement of initial clinical data from WP1066 clinician sponsored trial
Phase 1 surgical cohort begins
Transfer clinician sponsored trial WP1066 IND to Moleculin
Emory Physician Led Pediatric Medulloblastoma Trial begins
Announcement of further benefits of our sponsored research agreement with MD Anderson
Clinical Trial WP1220 - Announce filing and approval of CTA for WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL)
Assess WP1220 initial patient data
IND for IV formulated STAT3 inhibitor submitted
Dose first patient in Phase I trial for IV formulated STAT3 inhibitor
Announce further preclinical research results on WP1066 family
POTENTIAL TIMEFRAME
2019
2020
2020
Second Half of 2019
Accomplished and Ongoing into 2019
Accomplished
Q4-2019
2021
2021
Accomplished and ongoing 2019
METABOLISM/GLYCOSYLATION INHIBITOR ANTICIPATED MILESTONES
Begin preclinical work on WP1122
Complete formulation and begin manufacture of drug for trial
File IND or CTA for WP1122
POTENTIAL TIMEFRAME
Accomplished
First Half of 2020
2021
Pipeline
Milestones
